Paraquat Lawsuit Timeline: From MDL Centralization to the 2025 Settlement Agreement

2021-2023: the federal cases are centralized and prepared for testing

The JPML created MDL 3004 in June 2021 and sent federal Paraquat product-liability cases to the Southern District of Illinois. Plaintiffs generally alleged that occupational or environmental exposure to paraquat caused Parkinson's disease and that manufacturers failed to provide adequate warnings. Centralization created one forum for common discovery and expert issues. It was not a ruling that paraquat causes Parkinson's disease, and each plaintiff still needed admissible evidence about use, exposure, diagnosis, timing, and the responsible product.

The court selected an initial group of bellwether cases and established discovery, expert, and trial schedules. Bellwethers are intended to test recurring evidence in a manageable sample, but they remain individual lawsuits. During this period the parties exchanged corporate, scientific, medical, and case-specific evidence while the court addressed whether proposed experts used reliable methods under Federal Rule of Evidence 702. Those admissibility disputes became the pivotal event in the first trial program.

April 2024: the first bellwether cases fail at the expert stage

In April 2024, the court excluded plaintiffs' general-causation expert testimony in four initial bellwether cases and granted summary judgment to defendants in those selected actions. The decision focused on the methods and evidence offered by those plaintiffs, including the handling of epidemiology, dose, and biological mechanism. Without admissible general-causation testimony, the selected plaintiffs could not proceed to a jury on their claims.

That was a major defense result, but it should be described precisely. A Rule 702 ruling can influence later strategy without becoming a scientific declaration for all time. Other plaintiffs may have different experts, evidence, exposure histories, or legal issues. The court subsequently designed case-specific discovery and screening procedures for additional cases rather than terminating the entire MDL. Readers should distinguish a judgment in selected cases from dismissal of all filed actions.

Late 2024-2025: screening and settlement discussions reshape the docket

Orders issued in 2024 required plaintiffs to complete questionnaires, provide records, and comply with case-specific discovery. The court warned that noncompliance could lead to dismissal and entered orders governing cases filed after the original census period. These requirements matter because an MDL count may include actions at very different stages. A filed complaint is not the same as a verified exposure file, a trial-ready claim, or an accepted settlement participant.

By 2025, scheduled proceedings were repeatedly adjusted while the parties reported settlement work. A September 2025 agreement is now confirmed by a later court order, but the agreement itself is not reproduced in the public order reviewed here. This makes broad online claims about a paraquat settlement especially risky: the existence of an agreement is public, while its detailed qualification, valuation, release, and payment provisions may remain private or limited to represented inventories.

2026: the court confirms a settlement for certain claims

Case Management Order 24, filed April 8, 2026, states that co-lead plaintiffs' counsel and defendants executed a Master Settlement Agreement for Certain Individual Claims and Actions Involving Paraquat Products on September 3, 2025. It describes Special Master Randi Ellis's responsibilities for administration, qualification, and eligibility. It also orders administrators to provide information about people who did not qualify and eligible participants who opted out or indicated an intent to do so.

The careful phrase is 'certain individual claims and actions.' The order does not say every federal plaintiff settled, publish payment tiers, or invite the public to enroll. It also does not decide causation for nonparticipants. As of July 10, 2026, the responsible status statement is that an organized settlement exists for defined claims, administration remains court-supervised in part, and the terms needed to evaluate any particular person's rights are not supplied by the public order.

The science remains contested and must be reported as such

Human epidemiology does not reduce to a single verdict. A 2019 systematic review found a positive association in case-control studies but said the weight of evidence did not establish an indisputable cause-and-effect relationship. A 2024 California study reported higher odds of Parkinson's disease with modeled proximity to agricultural applications. Other reviews have emphasized exposure-measurement weaknesses, confounding, and the difference between experimental animal models and real-world human dose.

EPA's paraquat registration-review work is also a regulatory process, not a damages finding. Legal evaluation requires the actual product, application dates, work practices, protective equipment, diagnosis, alternative exposures, and state law. No one should infer personal causation from a timeline or stop medical treatment because litigation changed direction. Deadlines can be claim and jurisdiction specific; only counsel with the actual settlement materials can determine whether the 2025 agreement applies to a named claimant.

Reader questions

Frequently asked questions